Clinical Trial Update: A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

This Phase 2 randomized trial compared ARQ 197 (tivantinib) to gemcitabine in treatment-naïve patients with unresectable locally advanced or metastatic pancreat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• ARQ 197 (tivantinib) (tivantinib)
• Gemzar (gemcitabine)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED